Risk of Guillain-Barré Syndrome Following Recombinant Zoster Vaccine in Medicare Beneficiaries
- PMID: 34724025
- PMCID: PMC8561433
- DOI: 10.1001/jamainternmed.2021.6227
Risk of Guillain-Barré Syndrome Following Recombinant Zoster Vaccine in Medicare Beneficiaries
Abstract
Importance: Guillain-Barré syndrome can be reported after vaccination. This study assesses the risk of Guillain-Barré syndrome after administration of recombinant zoster vaccine (RZV or Shingrix), which is administered in 2 doses 2 to 6 months apart.
Objective: Use Medicare claims data to evaluate risk of developing Guillain-Barré syndrome following vaccination with zoster vaccine.
Design, setting, and participants: This case series cohort study included 849 397 RZV-vaccinated and 1 817 099 zoster vaccine live (ZVL or Zostavax)-vaccinated beneficiaries aged 65 years or older. Self-controlled analyses included events identified from 2 113 758 eligible RZV-vaccinated beneficiaries 65 years or older. We compared the relative risk of Guillain-Barré syndrome after RZV vs ZVL, followed by claims-based and medical record-based self-controlled case series analyses to assess risk of Guillain-Barré syndrome during a postvaccination risk window (days 1-42) compared with a control window (days 43-183). In self-controlled analyses, RZV vaccinees were observed from October 1, 2017, to February 29, 2020. Patients were identified in the inpatient, outpatient procedural (including emergency department), and office settings using Medicare administrative data.
Exposures: Vaccination with RZV or ZVL vaccines.
Main outcomes and measures: Guillain-Barré syndrome was identified in Medicare administrative claims data, and cases were assessed through medical record review using the Brighton Collaboration case definition.
Results: Amongst those who received RZV vaccinees, the mean age was 74.8 years at first dose, and 58% were women, whereas among those who received the ZVL vaccine, the mean age was 74.3 years, and 60% were women. In the cohort analysis we detected an increase in risk of Guillain-Barré syndrome among RZV vaccinees compared with ZVL vaccinees (rate ratio [RR], 2.34; 95% CI, 1.01-5.41; P = .047). In the self-controlled analyses, we observed 24 and 20 cases during the risk and control period, respectively. Our claims-based analysis identified an increased risk in the risk window compared with the control window (RR, 2.84; 95% CI, 1.53-5.27; P = .001), with an attributable risk of 3 per million RZV doses (95% CI, 0.62-5.64). Our medical record-based analysis confirmed this increased risk (RR, 4.96; 95% CI, 1.43-17.27; P = .01).
Conclusions and relevance: Findings of this case series cohort study indicate a slightly increased risk of Guillain-Barré syndrome during the 42 days following RZV vaccination in the Medicare population, with approximately 3 excess Guillain-Barré syndrome cases per million vaccinations. Clinicians and patients should be aware of this risk, while considering the benefit of decreasing the risk of herpes zoster and its complications through an efficacious vaccine, as risk-benefit balance remains in favor of vaccination.
Conflict of interest statement
Figures
![Figure 1.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8561433/bin/jamainternmed-e216227-g001.gif)
![Figure 2.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8561433/bin/jamainternmed-e216227-g002.gif)
![Figure 3.](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/8561433/bin/jamainternmed-e216227-g003.gif)
Comment in
-
In older adults, use of a recombinant zoster vaccine was associated with Guillain-Barré syndrome.Ann Intern Med. 2022 Mar;175(3):JC35. doi: 10.7326/J22-0010. Epub 2022 Mar 1. Ann Intern Med. 2022. PMID: 35226533
Similar articles
-
Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review.Hum Vaccin Immunother. 2023 Dec 31;19(1):2168952. doi: 10.1080/21645515.2023.2168952. Epub 2023 Mar 14. Hum Vaccin Immunother. 2023. PMID: 36916240 Free PMC article. Review.
-
An Analysis of Spontaneously Reported Data of Vesicular and Bullous Cutaneous Eruptions Occurring Following Vaccination with the Adjuvanted Recombinant Zoster Vaccine.Drug Saf. 2021 Dec;44(12):1341-1353. doi: 10.1007/s40264-021-01118-3. Epub 2021 Oct 7. Drug Saf. 2021. PMID: 34622421 Free PMC article. Review.
-
Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model.J Manag Care Spec Pharm. 2020 Dec;26(12):1567-1575. doi: 10.18553/jmcp.2020.20251. Epub 2020 Oct 12. J Manag Care Spec Pharm. 2020. PMID: 33043821 Free PMC article.
-
A Cost-Effectiveness Analysis of Vaccination for Prevention of Herpes Zoster and Related Complications: Input for National Recommendations.Ann Intern Med. 2019 Mar 19;170(6):380-388. doi: 10.7326/M18-2347. Epub 2019 Feb 19. Ann Intern Med. 2019. PMID: 30776797
-
Cost-effectiveness of an adjuvanted recombinant zoster vaccine in older adults in the United States who have been previously vaccinated with zoster vaccine live.Hum Vaccin Immunother. 2019;15(4):765-771. doi: 10.1080/21645515.2018.1558689. Epub 2019 Feb 20. Hum Vaccin Immunother. 2019. PMID: 30625011 Free PMC article.
Cited by
-
Guillain-Barré syndrome and COVID-19 vaccination: a systematic review and meta-analysis.J Neurol. 2024 Mar;271(3):1063-1071. doi: 10.1007/s00415-024-12186-7. Epub 2024 Jan 17. J Neurol. 2024. PMID: 38233678 Free PMC article.
-
Immunogenicity in Mice Immunized with Recombinant Adenoviruses Expressing Varicella-Zoster Virus Envelope Glycoprotein E.Viruses. 2023 Nov 22;15(12):2288. doi: 10.3390/v15122288. Viruses. 2023. PMID: 38140528 Free PMC article.
-
Healthy ageing: Herpes zoster infection and the role of zoster vaccination.NPJ Vaccines. 2023 Nov 28;8(1):184. doi: 10.1038/s41541-023-00757-0. NPJ Vaccines. 2023. PMID: 38017011 Free PMC article. Review.
-
Effectiveness and safety of recombinant zoster vaccine: A review of real-world evidence.Hum Vaccin Immunother. 2023 Dec 15;19(3):2263979. doi: 10.1080/21645515.2023.2263979. Epub 2023 Nov 15. Hum Vaccin Immunother. 2023. PMID: 37967254 Free PMC article. Review.
-
Efficacy and safety of the recombinant zoster vaccine: A systematic review and meta-analysis.Vaccine X. 2023 Oct 14;15:100397. doi: 10.1016/j.jvacx.2023.100397. eCollection 2023 Dec. Vaccine X. 2023. PMID: 37867572 Free PMC article. Review.
References
-
- Prevention CfDCa . Shingles | Signs and Symptoms | Herpes Zoster | CDC. Accessed March 9, 2020. https://www.cdc.gov/shingles/about/symptoms.html
-
- (FDA) FaDA . Shingrix package insert. 2017. Accessed May 16, 2018.https://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedPr...
-
- (CDC) CfDCaP . Guillain-Barré Syndrome. 2019.Accessed March 9, 2020. https://www.cdc.gov/vaccinesafety/concerns/guillain-barre-syndrome.html